The authors present a critique of a fellow surgeon's version of multimodali
ty therapy for patients with adenocarcinoma of the pancreas. Citing follow-
up studies, the authors prescribe adjustments in therapeutic specifics to f
oster a more efficient approach to patients that results in lower toxicity
and shorter treatment periods.